Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALV NASDAQ:OMER NASDAQ:VBIV NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$14.16-0.9%$13.58$7.30▼$16.32$712.81M-0.1781,849 shs1.42 million shsOMEROmeros$4.18-2.6%$3.80$2.95▼$13.60$284.49M2.37909,069 shs767,814 shsVBIVVBI Vaccines$0.23$0.06▼$1.35$1.87M2.183.66 million shs29.90 million shsVRCAVerrica Pharmaceuticals$5.23-2.2%$6.57$3.82▼$24.40$49.42M1.7842,896 shs39,800 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals+6.17%+8.59%+8.18%+5.54%+6.72%OMEROmeros+3.13%-2.05%+18.84%+28.44%+1.90%VBIVVBI Vaccines0.00%0.00%0.00%0.00%+262.78%VRCAVerrica Pharmaceuticals-4.29%-10.39%-5.14%-10.07%-77.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALVKalVista Pharmaceuticals3.9352 of 5 stars3.62.00.04.42.20.80.6OMEROmeros3.8964 of 5 stars3.40.00.04.43.61.70.6VBIVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals4.4597 of 5 stars3.14.00.04.73.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALVKalVista Pharmaceuticals 3.11Buy$26.2980.97% UpsideOMEROmeros 2.83Moderate Buy$18.00340.64% UpsideVBIVVBI Vaccines 0.00N/AN/AN/AVRCAVerrica Pharmaceuticals 2.20Hold$80.001,415.73% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, OMER, VBIV, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.008/15/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/15/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.007/25/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.006/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AOMEROmerosN/AN/AN/AN/A($3.36) per shareN/AVBIVVBI Vaccines$9.41M0.00N/AN/A$0.32 per share0.00VRCAVerrica Pharmaceuticals$7.57M6.59N/AN/A($1.85) per share-2.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALVKalVista Pharmaceuticals-$183.44M-$3.69N/AN/AN/AN/A-134.07%-82.65%9/4/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)VBIVVBI Vaccines-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/AVRCAVerrica Pharmaceuticals-$76.58M-$8.28N/AN/AN/AN/AN/A-115.48%11/3/2025 (Estimated)Latest VRCA, OMER, VBIV, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91N/AN/AN/A$1.97 millionN/A8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/12/2025Q2 2025VRCAVerrica Pharmaceuticals-$0.70$0.02+$0.72$0.02$4.37 million$12.70 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALVKalVista PharmaceuticalsN/A5.355.35OMEROmerosN/A0.810.81VBIVVBI VaccinesN/A0.340.21VRCAVerrica PharmaceuticalsN/A1.261.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALVKalVista PharmaceuticalsN/AOMEROmeros48.79%VBIVVBI Vaccines12.26%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipKALVKalVista Pharmaceuticals4.30%OMEROmeros12.90%VBIVVBI Vaccines10.35%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALVKalVista Pharmaceuticals10050.34 million48.18 millionOptionableOMEROmeros21068.06 million59.28 millionOptionableVBIVVBI Vaccines2228.68 million25.71 millionOptionableVRCAVerrica Pharmaceuticals409.45 million4.35 millionOptionableVRCA, OMER, VBIV, and KALV HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ...September 3 at 12:09 PM | bakersfield.comBArmistice Capital LLC Sells 353,600 Shares of Verrica Pharmaceuticals Inc. $VRCASeptember 3 at 6:30 AM | marketbeat.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2 at 7:00 AM | globenewswire.com101,125 Shares in Verrica Pharmaceuticals Inc. $VRCA Acquired by Kovitz Investment Group Partners LLCAugust 26, 2025 | marketbeat.comShort Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%August 22, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPSAugust 14, 2025 | marketbeat.comVerrica Posts Profit in Fiscal Q2August 14, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 13, 2025 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deVerrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comVerrica Pharmaceuticals Regains Nasdaq ComplianceAugust 12, 2025 | msn.comVerrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesAugust 12, 2025 | zacks.comVerrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.com3VRCA : What to Expect from Verrica Pharmaceuticals's EarningsAugust 11, 2025 | benzinga.comVerrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comVerrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025August 6, 2025 | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from BrokeragesAugust 5, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?August 3, 2025 | marketbeat.comVerrica Pharmaceuticals Implements Reverse Stock SplitAugust 1, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...July 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025How ServiceNow Is Turning AI Strategy Into Real RevenueBy Jeffrey Neal Johnson | August 22, 2025Wall Street Has Left Intel for Dead—Here's Why You Shouldn’tBy Jeffrey Neal Johnson | August 8, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 2025VRCA, OMER, VBIV, and KALV Company DescriptionsKalVista Pharmaceuticals NASDAQ:KALV$14.16 -0.13 (-0.91%) Closing price 04:00 PM EasternExtended Trading$14.18 +0.02 (+0.11%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Omeros NASDAQ:OMER$4.18 -0.11 (-2.56%) Closing price 04:00 PM EasternExtended Trading$4.18 0.00 (0.00%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.VBI Vaccines NASDAQ:VBIVVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Verrica Pharmaceuticals NASDAQ:VRCA$5.23 -0.12 (-2.24%) Closing price 04:00 PM EasternExtended Trading$5.23 0.00 (0.00%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
